glioma
Oncology · 2005–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| dabrafenib; trametinib Treatment of paediatric patients aged ≥12 months to <18 years with BRAF V600E mutation-positive low-grade glioma (LGG) with progressive disease following… | Dec 2024 | Recommended with restriction | input received |
| bevacizumab Treatment of relapsed or refractory glioblastoma in patients who have progressed on or are intolerant to temozolomide. | May 2019 | Recommended with restriction | unclear |
| carmustine Adjunct to surgery and radiation for newly-diagnosed high-grade malignant gliomas (Grade III and IV gliomas), including glioblastoma multiforme. | Mar 2006 | Not recommended | no section in document |
| carmustine Treatment of newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Medical Oncology Group
What the PBS pays
$107M in government benefit over 2024–25, across 86,344 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| dabrafenib and trametinib | $57.2M |
| bevacizumab | $49.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 4 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| vorasidenibVorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over | TA1147 | recommended | 2026-04 |
| dabrafenibDabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | recommended | 2024-05 |
| carmustine implants and temozolomideCarmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | recommended | 2007-06 |
| guidance on the use of temozolomideGuidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | recommended restricted | 2001-04 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.